Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

In the randomized phase II DREAMM-2 study, single-agent belantamab mafodotin demonstrated deep and durable responses and a manageable safety profile in triple-class refractory relapsed/refractory multiple myeloma (RRMM). We present patient-reported outcomes (PROs) from this study for patients treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Popat, Rakesh, Lonial, Sagar, Voorhees, Peter M., Esposti, Simona Degli, Gorsh, Boris, Gupta, Ira, Opalinska, Joanna, Sapra, Sandhya, Piontek, Trisha, He, Zangdong, Kleinman, David, Schaumberg, Debra, Regnault, Antoine, Meunier, Juliette, Eliason, Laurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Research & Scholarship
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558016/
https://www.ncbi.nlm.nih.gov/pubmed/37808071
http://dx.doi.org/10.6004/jadpro.2023.14.6.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558016/
https://www.ncbi.nlm.nih.gov/pubmed/37808071
http://dx.doi.org/10.6004/jadpro.2023.14.6.4

Ejemplares similares